Mural Oncology plc (NASDAQ:MURA – Get Free Report) shares were down 1.9% during trading on Thursday . The company traded as low as $3.44 and last traded at $3.53. Approximately 147,884 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 262,671 shares. The stock had previously closed at $3.60.
Analysts Set New Price Targets
Separately, Morgan Stanley started coverage on shares of Mural Oncology in a research report on Thursday, April 4th. They issued an “overweight” rating and a $13.00 price objective for the company.
Read Our Latest Research Report on MURA
Mural Oncology Trading Up 1.4 %
Mural Oncology (NASDAQ:MURA – Get Free Report) last announced its earnings results on Tuesday, March 26th. The company reported ($3.57) EPS for the quarter. Equities analysts predict that Mural Oncology plc will post -10.63 earnings per share for the current year.
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Read More
- Five stocks we like better than Mural Oncology
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 4/22 – 4/26
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Stocks Leading the U.S. Agriculture Comeback
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
